Daré Bioscience, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 8.04 million compared to USD 8.4 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4498 USD | +3.31% | -13.50% | +45.57% |
05-15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
05-14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.57% | 45.47M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023